Exclusive: We asked for biopharma's opinion about the plasma EUA. The industry offered a double-barreled response
FDA commissioner Stephen Hahn took to Twitter Monday night to walk back some of his unsubstantiated comments about plasma’s impact on Covid-19 and push a claim that the controversial EUA was all done by the book, but the damage he’s done to the agency’s reputation for independence and integrity may not be so easy to repair.
And that’s within the biopharma industry, which has been highly favorable to recent regulatory trends on drug reviews and access.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.